Breaking News, Financial News

4Q Financial Reports: GlaxoSmithKline

GlaxoSmithKline

4Q Revenues: $10.3 billion (+13%)

4Q Earnings: $1.9 billion (+45%)

FY Revenues: $37.8 billion (+8%)

FY Earnings: $8.2 billion (+20%)

Comments: Growth driven by key products: Seretide/Advair, Avandia and the company’s vaccines business. Sales of Seretide/Advair rose 22% to $5.2 billion and sales of Avandia rose 18% to $2.3 billion for the year. The company’s vaccines business posted total sales of $2.4 billion, up 15%, led by Infanrix vaccine. The company expects to file for approval for its cervical cancer vaccine, Cervarix, in the EU in March and in the U. S. before the end of the year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters